Purpose: This introductory study aims to analyze the association of serum vitamin D3 levels with recently detected myopia in Indian children following home confinement post-COVID-19 pandemic.
Methods: Children aged 5-15 years who had not attended physical school in the past 1 year and visited the ophthalmology department with various ocular symptoms were divided into two groups: the myopic group with recently detected myopia and the non-myopic group with ocular ailments other than myopia. All children underwent basic ophthalmic evaluation and a general physical examination. Blood samples were collected for serum vitamin D3 levels. A pretested questionnaire inquiring about the duration of exposure to a digital screen, outdoor activities, and socioeconomic status was filled out for all children.
Results: The mean serum vitamin D3 level in the myopic group was 28.17 ± 15.02 ng/dl in comparison to 45.36 ± 17.56 ng/dl in the non-myopic group (P value < 0.05). Linear regression of the data establishes that myopia is associated with hypovitaminosis D3 (OR- 13.12, 95% CI 2.90-50.32, a P value of 0.001). The correlation between spherical equivalent and vitamin D3 levels was significant (Pearson correlation value: 0.661). In the myopic group, 63.3% of children had screen use >6 hours against 43.3% of children in the non-myopic group. In the myopic group, 33.3% of the children had an outdoor activity duration of <2 hours against 6.6% of children in the non-myopic group.
Conclusion: This study proposes hypovitaminosis D3 as a strong factor associated with the development of myopia in children. Although it is a preliminary study, it suggests that the trial for vitamin D3 supplementation in young children to delay or cease the development of myopia is warranted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155583 | PMC |
http://dx.doi.org/10.4103/ijo.IJO_984_22 | DOI Listing |
Photodiagnosis Photodyn Ther
January 2025
Southwest Hospital/Southwest Eye Hospital, Army Medical University, Chongqing 400038, China.; Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing, China; Jinfeng Laboratory, Chongqing, China. Electronic address:
Purpose: Utilizing Swept source optical coherence tomography angiography (SS-OCTA) investigates the changes in the vascular characteristics of the choriocapillaris and larger vascular layers, including Sattler's and Haller's layers, in the macular region of young myopia patients, in order to to Enhance our comprehension of the underlying mechanisms of the pathogenesis of myopia.
Methods: A retrospective analysis was performed on 103 young adults (154 eyes) that underwent SS-OCTA. Axial lengths (AL) were measured, 64 eyes with AL < 26.
JAMA Ophthalmol
January 2025
Centre for Eye Research Ireland, Environmental and Sustainability Health Institute, Technological University Dublin, Dublin, Ireland.
Importance: Additional data are required regarding atropine treatment regimens for control of myopia progression.
Objective: To investigate the efficacy and safety of different atropine regimens for myopia in children.
Design, Setting, And Participants: This was a secondary analysis of the 3-year results of the 24-Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, called the MOSAIC2 trial.
Purpose: To evaluate a new regression-derived nomogram for high myopic astigmatism in small incision lenticule extraction (SMILE) surgery.
Methods: In this prospective study, data from 180 eyes with myopic astigmatism ranging from -2.50 to -4.
Purpose: To evaluate dynamic changes in ciliary parameters and Implantable Collamer Lens V4C (ICL) (STAAR Surgical) haptic position using mydriatic and miotic agents and their effects on the central and peripheral vault.
Methods: This study involved 80 eyes from 40 consecutive patients (mean age: 28.05 years; range: 19 to 42 years) examined 3 months after ICL implantation.
Purpose: To compare the clinical outcomes, surgical workflow, and patient satisfaction following small incision lenticule extraction (SMILE) performed with the VisuMax 800 in one eye and the VisuMax 500 in the contralateral eye (both Carl Zeiss Meditec).
Methods: This was a prospective, single-site clinical study of patients undergoing SMILE for myopia and myopic astigmatism between February 2022 and August 2023. Each patient underwent bilateral treatment using the VisuMax 800 (VM800 group) in one eye and the VisuMax 500 (VM500 group) in the contralateral eye.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!